TY - JOUR
T1 - 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism
T2 - A cohort study
AU - Lin, Chien Mu
AU - Doyle, Pat
AU - Tsan, Yu Tse
AU - Lee, Chang Hsing
AU - Wang, Jung Der
AU - Chen, Pau Chung
N1 - Funding Information:
The NHI reimbursement data of Taiwan is anonymized and maintained by the National Health Research Institute with strict confidentiality in accordance with the Personal Electronic Data Protection Law. This study was also approved by the Ethics Review Board of the National Taiwan University College of Public Health.
PY - 2014
Y1 - 2014
N2 - Purpose: To evaluate the association between 131I therapy for thyroid cancer and risk of developing primary hyperparathy roidism. Methods: This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of 131I therapy on the risk of developing primary hyperparathyroidism in the cohort. Results: A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 105 person-years. 131I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative 131I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing 131I dose (test for trend p =0.51). No interaction was found between 131I dose and age (p =0.94) or 131I dose and sex (p = 0.99). Conclusion: 131I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years.
AB - Purpose: To evaluate the association between 131I therapy for thyroid cancer and risk of developing primary hyperparathy roidism. Methods: This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of 131I therapy on the risk of developing primary hyperparathyroidism in the cohort. Results: A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 105 person-years. 131I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative 131I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing 131I dose (test for trend p =0.51). No interaction was found between 131I dose and age (p =0.94) or 131I dose and sex (p = 0.99). Conclusion: 131I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years.
UR - http://www.scopus.com/inward/record.url?scp=84897070645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897070645&partnerID=8YFLogxK
U2 - 10.1007/s00259-013-2541-5
DO - 10.1007/s00259-013-2541-5
M3 - Article
C2 - 23982456
AN - SCOPUS:84897070645
SN - 1619-7070
VL - 41
SP - 253
EP - 259
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 2
ER -